Drug class
Protease Inhibitors clinical trials
A class of medicines: the studies that test any of its 127 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Keep track of what changes. Save the protease inhibitors studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesMedicines in this class
Studies that test each. A study of two counts under both, and once above.
- Lopinavir-ritonavir drug combination
- 136
- Elbasvir-grazoprevir drug combination
- 31
- Nirmatrelvir and ritonavir drug combination
- 19
And 87 more, each tested in fewer studies.
Studies by the year they started
1,734 studies that test it; most in 2010 (114); 4 more planned to start later
| Year | Studies |
|---|---|
| 1995 | 1 |
| 1996 | 2 |
| 1997 | 8 |
| 1998 | 2 |
| 1999 | 17 |
| 2000 | 14 |
| 2001 | 15 |
| 2002 | 17 |
| 2003 | 28 |
| 2004 | 37 |
| 2005 | 57 |
| 2006 | 63 |
| 2007 | 66 |
| 2008 | 101 |
| 2009 | 104 |
| 2010 | 114 |
| 2011 | 106 |
| 2012 | 108 |
| 2013 | 72 |
| 2014 | 112 |
| 2015 | 114 |
| 2016 | 87 |
| 2017 | 81 |
| 2018 | 64 |
| 2019 | 52 |
| 2020 | 75 |
| 2021 | 61 |
| 2022 | 58 |
| 2023 | 37 |
| 2024 | 18 |
| 2025 | 22 |
| 2026 | 21 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Hepatitis C
- 206
- COVID-19
- 91
Who runs them
Industry 1,054 · Other 802
Bristol-Myers Squibb (112) · Merck Sharp & Dohme LLC (100) · Boehringer Ingelheim (77) · National Institute of Allergy and Infectious Diseases (NIAID) (72) · AbbVie (56) · National Cancer Institute (NCI) (49) · Pfizer (49) · Hoffmann-La Roche (47)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.
Testing one of them · 1,856
- Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone MarrowRecruitingPhase 1/2University of California, IrvineNCT07281781Written as Nelfinavir
- A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe DiseaseRecruitingPhase 3ShionogiNCT07743580Written as Secutrelvir
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket TrialRecruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT06381661Written as Sivelestat
- A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)RecruitingPhase 2Daré Bioscience, Inc.NCT07601074Written as Lopinavir / ritonavir
- A Clinical Study of Ixazomib to Reactivate HIV and Reduce HIV Reservoir SizeNot yet recruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT07881809Written as Ixazomib 4 mg
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsRecruitingPhase 4Gilead SciencesNCT06337032Written as ATV
- Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)RecruitingPhase 4CSL BehringNCT07326592Written as CE1226
- A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe DiseaseRecruitingPhase 3PfizerNCT06679140Written as ibuzatrelvir
- A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely ImmunocompromisedRecruitingPhase 3PfizerNCT07013474Written as ibuzatrelvir
- Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)Enrolling by invitationPhase 4Baylor Research InstituteNCT07547878Written as Univasc
- Effect of Alpha-1 Antitrypsin Supplementation on Alcohol-Associated HepatitisRecruitingPhase 2Medical University InnsbruckNCT06582329Written as Alfa1 Antitrypsin
- Safety and Efficacy Study of Sivelestat in Neuromyelitis Optica Spectrum DisorderRecruitingPhase 1/2Kyushu UniversityNCT07738952Written as Sivelestat sodium hydrate
- Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)RecruitingPhase 4KalVista Pharmaceuticals, Ltd.NCT07654829Written as KVD900 600 mg
- Oral Fosamprenavir for GERDNot yet recruitingPhase 2Medical College of WisconsinNCT06704100Written as Fosamprenavir Calcium 700 MG Oral Tablet
- Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme ReductionRecruitingPhase 2Medical College of WisconsinNCT04383262Written as Fosamprenavir Calcium
- Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV RemissionRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT02140255Written as Lopinavir/Ritonavir (LPV/r)
- A Study of SDX-7320 in Combination With Eribulin for People With Breast CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05570253Written as SDX-7320
- Study of Secutrelvir in Participants With COVID-19RecruitingPhase 3ShionogiNCT07746544Written as Secutrelvir
- An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in AfricaNot yet recruitingPhase 3University College, LondonNCT07792096Written as Darunavir (DRV)
- Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIVRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT07040319Written as Glecaprevir/pibrentasvir
See all 1,856 studies that test one of the protease inhibitors →
Codes
What other systems call Protease Inhibitors · ClinicalTrials.gg INT008120
- MeSH (NLM) D011480Protease InhibitorsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D011480 | Protease Inhibitors | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.